GCIQ&A: hVivo’s Mo Khan on the company’s latest mega-deal
Mo Khan, chief executive of (HVO ), tells Vox about a new £17m human challenge contract with an existing customer, and the progress the company’s made to deliver better than expected results this year.
0:41 Mo Khan explains the details of the latest human challenge contract, a £17m deal with an existing top 5 global pharma group to test its respiratory syncytial virus (“RSV”) antiviral drug candidate, to be delivered over 2024 and 2025.
2:35 How this multi multi-cohort trial differs from the more common drug-versus-placebo approach, allowing customers to assess dosing as well as efficacy by more closely mirroring real world disease progress and further derisk
5:32 A flavour of this year’s numbers and how operational efficiencies have driven Ebitda margins over 20%, of which further details will be provided in a fuller trading update in January.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.